Taken the short-term response to pharmacological treatment together with the manifestation of increased protein expression as function of PCa disease progression might serve as evidence to develop new treatment targets outside the PI3K-AKT-mTOR/AR pathways in PCa. This evidence concerns the gene AKT1 and posterior cortical atrophy.